NCT06636032View on ClinicalTrials.gov

Dose Escalation of Allogeneic Adipose Derived Stroma/Stem Cells for the Treatment of Crohn's Fistula

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Crohn Disease
Interventions
DRUG

AdMSC (CellReady®)

At day 0, patients will have AdMSC injections. Patients will be followed-up for 6 months

Trial Locations (1)

Unknown

Toulouse Hospital, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT06636032 - Dose Escalation of Allogeneic Adipose Derived Stroma/Stem Cells for the Treatment of Crohn's Fistula | Biotech Hunter | Biotech Hunter